Giant cell myocarditis after first dose of BNT162b2 – a case report
Valentin G. Hirsch, Sven Schallhorn, Carolin Zwadlo, Johanna Diekmann, Florian Länger, Danny Jonigk, Tibor Kempf, Heinz‐Peter Schultheiß, Johann Bauersachs
Abstract
Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.
Topics & Concepts
MedicineMyocarditisAngiologyContext (archaeology)EtiologyTroponinTroponin THeart failureInternal medicinePediatricsCardiologyIntensive care medicinePaleontologyBiologyMyocardial infarctionViral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies